<?xml version='1.0' encoding='utf-8'?>
<document id="26852075"><sentence text="Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer."><entity charOffset="18-37" id="DDI-PubMed.26852075.s1.e0" text="Abiraterone Acetate" /><entity charOffset="43-53" id="DDI-PubMed.26852075.s1.e1" text="Prednisone" /><entity charOffset="58-67" id="DDI-PubMed.26852075.s1.e2" text="Docetaxel" /><pair ddi="false" e1="DDI-PubMed.26852075.s1.e0" e2="DDI-PubMed.26852075.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26852075.s1.e0" e2="DDI-PubMed.26852075.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s1.e0" e2="DDI-PubMed.26852075.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26852075.s1.e1" e2="DDI-PubMed.26852075.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s1.e1" e2="DDI-PubMed.26852075.s1.e2" /></sentence><sentence text="Coadministration of docetaxel and abiraterone acetate plus prednisone (AA + P) may benefit patients with metastatic castration-resistant prostate cancer (mCRPC) because of complementary mechanisms of action"><entity charOffset="20-29" id="DDI-PubMed.26852075.s2.e0" text="docetaxel" /><entity charOffset="34-53" id="DDI-PubMed.26852075.s2.e1" text="abiraterone acetate" /><entity charOffset="59-69" id="DDI-PubMed.26852075.s2.e2" text="prednisone" /><pair ddi="false" e1="DDI-PubMed.26852075.s2.e0" e2="DDI-PubMed.26852075.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26852075.s2.e0" e2="DDI-PubMed.26852075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s2.e0" e2="DDI-PubMed.26852075.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26852075.s2.e1" e2="DDI-PubMed.26852075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s2.e1" e2="DDI-PubMed.26852075.s2.e2" /></sentence><sentence text=" COU-AA-206 was a phase 1b study to determine the safe dose combination of docetaxel and AA + P in three cohorts of chemotherapy-naïve mCRPC patients"><entity charOffset="75-84" id="DDI-PubMed.26852075.s3.e0" text="docetaxel" /></sentence><sentence text=" Twenty-two patients received escalating doses of docetaxel plus AA + P"><entity charOffset="50-59" id="DDI-PubMed.26852075.s4.e0" text="docetaxel" /></sentence><sentence text=" The primary endpoint was the proportion of patients with a dose-limiting toxicity (DLT) between weeks 2 and 7" /><sentence text=" The recommended phase 2 dose (RP2D) was the highest safe combination of docetaxel plus AA + P"><entity charOffset="73-82" id="DDI-PubMed.26852075.s6.e0" text="docetaxel" /></sentence><sentence text=" Prostate-specific antigen (PSA) changes and intensive pharmacokinetic parameters for each drug were evaluated" /><sentence text=" Docetaxel 75mg/m2 + AA 1000mg + P 10mg was deemed the RP2D, with DLT in one of six patients"><entity charOffset="1-10" id="DDI-PubMed.26852075.s8.e0" text="Docetaxel" /></sentence><sentence text=" PSA declines from baseline of ≥50% and ≥90% were observed for 85" /><sentence text="7% and 66" /><sentence text="7% of patients, respectively" /><sentence text=" During median follow-up of 14" /><sentence text="5 mo, eight patients had PSA progression and six had radiographic progression or died" /><sentence text=" Systemic exposure was comparable for docetaxel and abiraterone when given alone or in combination"><entity charOffset="38-47" id="DDI-PubMed.26852075.s14.e0" text="docetaxel" /><entity charOffset="52-63" id="DDI-PubMed.26852075.s14.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.26852075.s14.e0" e2="DDI-PubMed.26852075.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26852075.s14.e0" e2="DDI-PubMed.26852075.s14.e1" /></sentence><sentence text=" Studies are ongoing to confirm the efficacy of potent androgen receptor-targeted therapy plus taxane in early mCRPC"><entity charOffset="55-63" id="DDI-PubMed.26852075.s15.e0" text="androgen" /><entity charOffset="95-101" id="DDI-PubMed.26852075.s15.e1" text="taxane" /><pair ddi="false" e1="DDI-PubMed.26852075.s15.e0" e2="DDI-PubMed.26852075.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26852075.s15.e0" e2="DDI-PubMed.26852075.s15.e1" /></sentence><sentence text="" /><sentence text="The combination of hormonal therapy and chemotherapy may improve outcomes in men with metastatic prostate cancer" /><sentence text=" This study demonstrates the ability to combine the hormonal therapy agent abiraterone acetate, plus prednisone, and the chemotherapy drug docetaxel with an acceptable side effect profile"><entity charOffset="75-94" id="DDI-PubMed.26852075.s18.e0" text="abiraterone acetate" /><entity charOffset="101-111" id="DDI-PubMed.26852075.s18.e1" text="prednisone" /><entity charOffset="139-148" id="DDI-PubMed.26852075.s18.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.26852075.s18.e0" e2="DDI-PubMed.26852075.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26852075.s18.e0" e2="DDI-PubMed.26852075.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s18.e0" e2="DDI-PubMed.26852075.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26852075.s18.e1" e2="DDI-PubMed.26852075.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26852075.s18.e1" e2="DDI-PubMed.26852075.s18.e2" /></sentence><sentence text=" A high rate of prostate-specific antigen decline was seen, but the study was small and additional research is needed before this becomes a standard approach" /><sentence text="" /></document>